Modern Head and Neck Cancer Care in Algeria: Beyond Cure Alone

Head and neck squamous cell carcinoma (HNSCC) remains one of the most challenging solid tumors in medical oncology. Successful treatment requires more than achieving locoregional control—it demands preserving speech, swallowing, nutrition, and quality of life while maximizing survival. As therapeutic options continue to expand, management has become increasingly individualized, relying on multidisciplinary expertise, careful patient selection, and the integration of modern systemic therapies.

The 2026 Algerian National Therapeutic Guidelines reflect this contemporary approach, emphasizing that treatment should be tailored according to tumor stage, anatomical site, resectability, patient fitness, and disease biology. Rather than relying on a single modality, optimal outcomes are achieved through the coordinated use of surgery, radiotherapy, systemic therapy, and comprehensive supportive care.

Multidisciplinary care drives therapeutic decisions

The management of head and neck cancers begins with accurate diagnosis, high-quality imaging, and precise pathological evaluation. Every patient benefits from discussion within a multidisciplinary tumor board, where head and neck surgeons, medical oncologists, radiation oncologists, radiologists, pathologists, and supportive care specialists jointly determine the most appropriate treatment strategy.

This collaborative approach recognizes that therapeutic success is measured not only by survival but also by long-term functional outcomes. Preserving speech, swallowing, and appearance has become an essential objective of modern treatment planning, particularly for patients with potentially curable disease.

Curative treatment is increasingly personalized

For patients with resectable tumors, surgery remains the cornerstone of curative treatment whenever complete oncologic resection can be achieved while preserving acceptable function. Postoperative radiotherapy or concurrent chemoradiotherapy is recommended according to pathological risk factors, reinforcing the importance of individualized risk-adapted treatment.

For selected patients with locally advanced disease, definitive concurrent chemoradiotherapy continues to represent a standard organ-preservation strategy. Cisplatin-based chemoradiation remains the preferred radiosensitizing approach for eligible patients, highlighting the continued central role of platinum chemotherapy in curative management.

Rather than following a uniform therapeutic algorithm, current practice increasingly focuses on selecting the treatment strategy that offers the best balance between disease control, functional preservation, and treatment-related toxicity for each individual patient.

Systemic therapy has entered a new era

One of the most significant developments in head and neck oncology has been the evolution of systemic therapy. While chemotherapy continues to play a critical role in locally advanced disease, treatment options for recurrent and metastatic cancer have expanded considerably with the incorporation of immunotherapy into routine clinical practice.

Therapeutic decisions are now guided by multiple factors, including previous treatments, performance status, disease burden, and biomarker assessment. This individualized approach allows clinicians to tailor systemic therapy according to each patient’s clinical profile rather than applying a one-size-fits-all strategy.

The growing integration of immunotherapy reflects a broader transformation in oncology, where advances in tumor biology are progressively reshaping therapeutic decision-making.

Biomarkers are becoming integral to treatment selection

Modern management increasingly recognizes the importance of biomarkers in guiding therapeutic choices. PD-L1 expression has become an important component of decision-making for recurrent and metastatic disease, helping identify patients most likely to benefit from immune checkpoint inhibitors.

Similarly, HPV status has significant prognostic implications in oropharyngeal squamous cell carcinoma and contributes to treatment discussions and risk stratification. As access to molecular diagnostics continues to expand, biomarker-driven care is expected to play an increasingly important role in routine oncology practice.

Supportive care is a therapeutic priority

Effective management extends well beyond anticancer treatment. Nutritional assessment, dental evaluation before radiotherapy, pain control, speech and swallowing rehabilitation, psychosocial support, and close symptom monitoring all contribute directly to treatment tolerance and clinical outcomes.

Recognizing supportive care as an essential therapeutic intervention reflects the evolution of modern oncology toward comprehensive, patient-centered management throughout the entire cancer journey.

Clinical Perspective

Head and neck cancer management has evolved from a modality-based approach to a patient-centered therapeutic strategy that integrates surgery, radiotherapy, systemic treatment, biomarkers, and supportive care. The 2026 Algerian National Therapeutic Guidelines embrace this philosophy by promoting individualized treatment pathways built on multidisciplinary collaboration and evidence-based decision-making. As therapeutic options continue to expand, the future of head and neck oncology will increasingly depend not only on access to innovative treatments but also on selecting the right treatment for the right patient while preserving function and quality of life.

Written by Dr. Imène Hadji, MD
Medical Oncologist | Algeria Hub Lead, OncoDaily